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Sir,
We thank you for providing us the opportunity to respond to
the Letter to the Editor received by your office in response to our
article ‘Sunitinib and bevacizumab for first-line treatment of
metastatic renal cell carcinoma: a systematic review and indirect
comparison of clinical effectiveness’ (Thompson Coon et al, 2009).
We are pleased that Professor Mickisch recognises the need for
and importance of indirect treatment comparisons in the absence
of head-to-head comparisons and welcome a debate on the relative
merits of indirect treatment comparison methods.
It appears that some of the comments outlined by Professor
Mickisch stem from a misunderstanding of the methods used in
our analysis. Ideally we would have given a more detailed account
in the paper, but owing to restrictions in the length of the article
we chose to rely on the cited reference (Ades, 2003) to provide a
fuller description of the methods used. Our analysis was mainly
conducted within the Bayesian framework and as such issues
relating to frequentist hypothesis testing are not applicable.
Our analysis compared the reported differences (hazard ratios)
between the three treatments rather than comparing the absolute
effects of sunitinib with those of bevacizumab plus IFN and those
of IFN alone. Accordingly, it is important to clarify that we did not
use a one-sided t-test to calculate the P-value, as inferred by
Professor Mickisch. We acknowledge that the language used in
describing the output from the MCMC as a one-sided P-value may
give rise to some interpretation issues for an audience who are
more familiar with frequentist hypothesis testing than Bayesian
analysis. The P-value obtained from the MCMC – although
regarded as equivalent to that obtained from a one-sided test –
is in reality a direct estimate of the probability that one treatment
is better than another. It is one of the advantages of the Bayesian
approach that it enables intuitive probability statements to be
made about propositions; in this case, 0.0272 is an estimate of the
probability that bevacizumab provides superior PFS gain to
sunitinib. As a result, within the context of our analysis, it would
have been neither possible nor desirable to adopt the methods
suggested by Professor Mickisch, which relate solely to the
frequentist paradigm.
In terms of the number of simulations used in our analysis, we
are unaware of any references suggesting that simulation
numbers should be as low as 2000 iterations in an MCMC and
we would be interested in the source of Professor Mickisch’s
comments. It is important to clarify that we were not simulating
individual patient experiences but rather repeatedly sampling the
differences between treatments in each of the uncertain distribu-
tions (i.e., our analysis was at the level of a cohort of patients as
reflected in trial results). Accordingly, cautions that apply to, for
example, bootstrap sampling of individual patient data are not
applicable in this instance. Increasing the number of simulations
in an MCMC will produce a more accurate estimate (with less
possibility of the outputs being distorted by outlying or extreme
simulations), but will not result in spurious certainty (in other
words, the posterior distribution will become smoother, but not
narrower).
Notwithstanding the relevance of guidance from the Canadian
Agency for Drugs and Technologies in Health (CADTH) to this
work, we do not share Professor Mickisch’s conclusion that they
have identified the Bucher method as the ‘gold standard’ method
for performing indirect treatment comparisons. The CADTH
identifies both the Bucher and the Bayesian multiple treatment
comparison MTC methods as suitable for conducting indirect
treatment comparisons, and concludes that the MTC is elegant and
more widely applicable, although it may be perceived to be
computationally complex. We feel that the MTC approach is more
appropriate in this instance as it uses the data from all three
available studies in one analysis, thereby handling all the
uncertainty at the same time. In contrast, the Bucher method
necessitates a two-step analysis in which we would first need to
meta-analyse the results from the two trials of bevacizumab plus
IFN vs IFN and then perform the indirect comparison of this
pooled result with the result of the trial of sunitinib vs IFN. In fact,
because the number of trials is small and the evidence network
simple, in this instance, performing this analysis on the dataset
used in our article produces results that are almost identical to
those generated in the Bayesian analysis: HR¼0.796 (95% CI:
0.629, 1.007).
As our analysis was concerned with differences between
treatments estimated in randomised comparisons, we were unable
to utilise the data originating from the single-arm expanded access
trial (Gore et al, 2007) cited in the letter, in which participants
received sunitinib only. We are unclear as to why Professor
Mickisch does not regard the trial by Rini and colleagues as
*Correspondence: Dr JS Thompson Coon;
E-mail: jo.thompson-coon@pms.ac.uk
British Journal of Cancer (2010) 102, 234–235
& 2010 Cancer Research UK All rights reserved 0007– 0920/10 $32.00
www.bjcancer.comproviding useful data to incorporate into his ongoing
research. Although the trial was open-label in design, a large
number of individuals (n¼732) were randomised to receive either
bevacizumab plus IFN or IFN alone, and the treatment effects
reported to date with respect to progression-free survival are
similar to those seen in the trial reported by Escudier and
colleagues. We assume that a full peer-reviewed presentation of
Professor Mikisch’s methods, data, and results will be available in
due course, and look forward to reading his findings.
We hope that these points serve to clarify both the methods and
the outputs of our analysis and once again thank you for giving us
the opportunity to engage in the debate.
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